Mallinckrodt Plc Ordinary Share (MNK) 74.55

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mallinckrodt Plc Ordinary Share (MNK) 74.55 $MNK

Allergan Takes Over RetroSense; Boosts Eye Care Pipeline
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 9:20AM CDT
Allergan plc (AGN) has acquired RetroSense Therapeutics, a privately held, clinical-stage biotechnology company, which will add the latter's lead gene therapy development program RST-001 to its eye care pipeline.
MNK: 74.55 (-0.37), AGN: 238.42 (-0.70), AXGN: 9.00 (+0.06), AMPH: 19.03 (+0.12)

Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PR Newswire - Wed Aug 31, 4:00PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced it closed the acquisition of Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft® regenerative skin tissue and a technology platform for genetically enhanced skin tissues.
MNK: 74.55 (-0.37)

Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 74.55 (-0.37), TSLA: 201.71 (-1.12), ENDP: 20.30 (-0.19), F: 12.70 (+0.03), MDT: 86.15 (-1.02), GME: 28.13 (-0.24), MYL: 40.31 (-0.09), PDCO: 47.18 (+0.18), TIF: 69.78 (+0.61), BA: 132.64 (-0.35), ESRX: 72.67 (-0.05), STJ: 79.18 (+0.28), SSYS: 21.97 (-0.79), TECD: 73.62 (+0.78), ADSK: 68.60 (+0.91)

Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.55 (-0.37), CATB: 4.30 (-0.57), ANIP: 60.71 (-0.84), SRPT: 28.46 (+0.67)

Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 74.55 (-0.37), MDCO: 37.38 (-0.86), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25)

Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND Application
PR Newswire - Thu Aug 25, 6:30AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted the company's request for a Fast Track designation for its Investigational New Drug (IND) application for Synacthen® Depot in the treatment of Duchenne muscular dystrophy (DMD). Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is approved and marketed outside of the U.S. for certain autoimmune and inflammatory conditions, but has never been approved for use in patients in the U.S.
MNK: 74.55 (-0.37)

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million
PR Newswire - Wed Aug 24, 7:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM), for approximately $690 million before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations.
MNK: 74.55 (-0.37)

Extracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs
PR Newswire - Tue Aug 23, 7:00AM CDT
Approval granted for reimbursement of Extracorporeal Photopheresis (ECP) for Bronchiolitis Obliterans Syndrome (BOS) derived from lung transplantation.
MNK: 74.55 (-0.37)

Mallinckrodt To Present At Morgan Stanley Global Healthcare Conference
PR Newswire - Mon Aug 22, 6:30AM CDT
Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Monday, Sept. 12, 2016, at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York, 109 E. 42nd St., New York.
MNK: 74.55 (-0.37), MS: 31.69 (-0.06)

Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment
PR Newswire - Thu Aug 18, 6:55AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today it will build out a new campus for its fast-growing Specialty Brands organizations in the Somerset Financial Center, 1405-1425 Route 206, in Bedminster. Mallinckrodt will invest greater than $80 million in New Jersey, and anticipates approximately 400 employees will occupy the new space in the first quarter of 2017.
MNK: 74.55 (-0.37)

Mallinckrodt (MNK) to Buy Stratatech for Undisclosed Value
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 11:24AM CDT
Mallinckrodt plc (MNK) announced that it will acquire privately held regenerative medicine company, Stratatech Corporation.
MNK: 74.55 (-0.37), MDCO: 37.38 (-0.86), CORT: 5.71 (+0.23), PCRX: 40.54 (-0.25)

Blog Coverage Mallinckrodt Acquires Privately Held Regenerative Skin Technology Firm
ACCESSWIRE - Fri Aug 12, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 12, 2016 / Active Wall St. blog coverage looks at the headline from Mallinckrodt PLC (NYSE: MNK) as the company announced on August 10, 2016, that it has entered into an agreement with Stratatech Corp. to acquire the company which specializes in the manufacture of regenerative skin and skin substitute products. The financial details were not disclosed at the time of announcement and the deal is expected to close in the second half of 2016. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
MNK: 74.55 (-0.37)

Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PR Newswire - Wed Aug 10, 4:45PM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.
MNK: 74.55 (-0.37)

Gilead Sciences, Williams Companies, Procter & Gamble, Mallinckrodt Public Limited Company, and Western Digital and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Wed Aug 03, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, MNK, PG, WDC, and WMB.
MNK: 74.55 (-0.37), GILD: 78.22 (+0.34), WMB: 30.34 (+1.18), PG: 87.95 (-0.69), WDC: 53.30 (+5.75)

Mallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:51PM CDT
Mallinckrodt plc (MNK) reported adjusted earnings of $2.20 per share in the third quarter of fiscal 2016 (ended Jun 24, 2016), beating the Zacks Consensus Estimate of $2.01.
MNK: 74.55 (-0.37), IPXL: 24.47 (+0.23), SUPN: 22.51 (+0.32), MYL: 40.31 (-0.09)

Royal Caribbean and General Motors fall; CVS advances
AP - Tue Aug 02, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MNK: 74.55 (-0.37), DISCK: 24.44 (-0.03), F: 12.70 (+0.03), DAL: 38.90 (+2.08), PFE: 34.84 (+0.07), STX: 36.51 (+2.04), DISCB: 27.25 (+0.05), DISCA: 25.07 (-0.02), CVS: 93.61 (+0.25), GM: 31.89 (-0.23)

Mallinckrodt (MNK) Tops on Earnings & Sales in Q3
Ekta Bagri - Zacks Investment Research - Tue Aug 02, 5:48AM CDT
Mallinckrodt beat on earnings by a wide margin. Our consensus called for EPS of $2.01, and the company reported EPS of $2.20.
MNK: 74.55 (-0.37)

Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016
PR Newswire - Tue Aug 02, 5:00AM CDT
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the third quarter of fiscal 20161. Unless otherwise noted, all comparisons of fiscal 2016 third quarter or year-to-date performance are to the comparable periods of fiscal 2015.
MNK: 74.55 (-0.37)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.55 (-0.37), BIIB: 312.30 (+1.63), ABT: 41.90 (-0.26), JNJ: 119.61 (-0.14), GILD: 78.22 (+0.34), MRK: 62.87 (-0.37), PFE: 34.84 (+0.07), SGNT: 21.76 (+0.03), ABBV: 64.97 (+0.36), PRTA: 55.33 (+0.82), NVS: 80.36 (+0.21)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 59

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 68

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 114

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 114

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 71

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 57

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 95

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Sanoma Corporation's Recent Share Buyback Explained

Updated Category News Views 173

Insights into Sanoma Corporation's Share Buyback Activity Sanoma Corporation has conducted a significant share buyback, underscoring its commitment to enhancing shareholder value. These transactions were announced through a stock exchange release, giving investors an insightful look into the company's market activities. Details of the Buyback Transaction On a noteworthy...

Continue Reading
Finland's Real Estate Market Thrives in 2025: Key Insights

Updated Category News Views 248

The Resurgence of Finland's Real Estate Market Finland's real estate market is experiencing an inspiring recovery, marked by increasing transaction volumes and growing investment liquidity. This positive trend not only showcases renewed confidence among local investors but also reflects heightened interest from international players in the Finnish market. Analysts predict...

Continue Reading
Investors Alert: Join the Fight for Justice with aTyr Pharma

Updated Category News Views 190

Understanding the aTyr Pharma Situation Investors of aTyr Pharma Inc. are facing a challenging and distressing time following recent revelations regarding the company’s performance. The company is known for its innovative approaches in the realm of pharmaceuticals and has garnered significant attention in the stock market. However, the recent downturn in share value has...

Continue Reading
Fly Play hf. Reports Q2 Losses Amid External Challenges

Updated Category News Views 143

Profit Warning for Fly Play hf. Recently, Fly Play hf. shared concerns regarding its upcoming Q2 2025 interim financial report. The company anticipates that their results will fall short of last year’s performance and internal expectations. A net loss of around USD 16 million is projected for this quarter, compared to a loss of USD 10 million during the same period last...

Continue Reading
Olin Corporation Faces Challenges Amid Earnings Report

Updated Category News Views 85

Olin Corporation Reports Disappointing Third Quarter Earnings Olin Corporation (NYSE: OLN) recently announced its earnings for the third quarter of 2024, revealing significant challenges that led to a 14% drop in its stock price. This downturn was driven primarily by the fallout from Hurricane Beryl and a decline in demand within its ammunition division. Financial...

Continue Reading